Who are MR13A9's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CDobi, senfrol monotherapy, Empagliflozin + Carvedilol, B55R1 and B55R2, NBF, FPT-20.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mr13a9.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MR13A9 — Competitive Intelligence Brief

MR13A9 (MR13A9) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 (Sodium-Glucose Cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

MR13A9 (MR13A9) — Kissei Pharmaceutical Co., Ltd.. MR13A9 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MR13A9 TARGET	MR13A9	Kissei Pharmaceutical Co., Ltd.	phase 3	SGLT2 inhibitor	SGLT2 (Sodium-Glucose Cotransporter 2)
CDobi	CDobi	Services Hospital, Lahore	marketed	SGLT2 inhibitor	SGLT2
senfrol monotherapy	senfrol monotherapy	Peking University Third Hospital	marketed	SGLT2 inhibitor	SGLT2
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)
B55R1 and B55R2	B55R1 and B55R2	AJU Pharm Co., Ltd.	marketed	SGLT2 inhibitor	SGLT2
NBF	NBF	Universidad Complutense de Madrid	marketed	SGLT2 inhibitor	SGLT2
FPT-20	FPT-20	Trieu, Nguyen Thi, M.D.	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MR13A9 — Competitive Intelligence Brief. https://druglandscape.com/ci/mr13a9. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab